NEEDLE-FREE HOPE: IONTOPHORESIS FOR BETTER QUALITY OF LIFE IN ORAL SUBMUCOUS FIBROSIS

Background: Oral submucous fibrosis (OSMF) is a progressive, potentially malignant condition of the oral mucosa, linked chiefly to areca nut chewing and frequently to tobacco as well. Patients live with burning, mucosal stiffness and a mouth that opens a little less each year, and these changes touch eating, speech, social life and peace of mind. Medical management still leans heavily on intralesional injections given over many visits; they hurt, they work slowly, and a good number of patients give up before the course ends. Iontophoresis, in which a weak electric current carries a charged drug into tissue, offers a way of giving the same medicines without a needle. Aim: To trace how OSMF develops, describe what it does to a patient’s quality of life (QoL), examine how conventional treatment adds to that burden, and judge whether iontophoresis can reasonably be expected to make patients’ lives better. Methods: Narrative review of peer-reviewed literature on OSMF, quality of life, conventional treatment and iontophoretic drug delivery. Results: OHIP-14 scores in OSMF are close to five times those of healthy controls and worsen with stage. Fear of cancer, anxiety and depression are frequent. A course of injections can mean anywhere from 6 to 26 visits, and in routine practice the gain in mouth opening is often small, with roughly a third of patients not completing treatment. Only two studies of iontophoresis in OSMF have been published. Both were carried out on animal tissue in the laboratory and recorded a 6.5- to 13-fold rise in mucosal drug uptake after 5 to 10 minutes of current. Conclusion: The main appeal of iontophoresis lies in easing the burden of treatment, a problem that has received little attention in OSMF care. Whether it actually improves patients’ quality of life remains untested in humans, and trials that place QoL at the centre are required.